Next Article in Journal
Photoacoustic Imaging Probes Based on Tetrapyrroles and Related Compounds
Next Article in Special Issue
Human Endometrial Carcinogenesis Is Associated with Significant Reduction in Long Non-Coding RNA, TERRA
Previous Article in Journal
Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner
Previous Article in Special Issue
ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 9
10.3390/ijms21093080
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Sinomenine Inhibits Migration and Invasion of Human Lung Cancer Cell through Downregulating Expression of miR-21 and MMPs

by
Kun-Hung Shen
1,2,†,
Jui-Hsiang Hung
3,†,
Yi-Ching Liao
3,
Shu-Ting Tsai
3,
Ming-Jiuan Wu
3 and
Pin-Shern Chen
3,*
1
Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan
2
Department of Urology, Taipei Medical University, Taipei 110, Taiwan
3
Department of Biotechnology, Chia Nan University of Pharmacy & Science, Tainan 71710, Taiwan
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2020, 21(9), 3080; https://doi.org/10.3390/ijms21093080
Submission received: 12 April 2020 / Accepted: 24 April 2020 / Published: 27 April 2020
(This article belongs to the Special Issue Noncoding RNAs in Cancer: From Cancer Stem Cells to Invasion and Metastases)
Browse Figures
Review Reports Versions Notes

Abstract

:
Sinomenine is an alkaloid derived from Sinomenium acutum. Recent studies have found that sinomenine can inhibit various cancers by inhibiting the proliferation, migration and invasion of tumors and inducing apoptosis. This study aims to investigate the effect and mechanism of sinomenine on inhibiting the migration and invasion of human lung adenocarcinoma cells in vitro. The results demonstrate that viabilities of A549 and H1299 cells were inhibited by sinomenine in a dose-dependent manner. When treated with sub-toxic doses of sinomenine, cell migration and invasion are markedly suppressed. Sinomenine decreases the mRNA level of matrix metalloproteinase-2 (MMP-2), MMP-9, and the extracellular inducer of matrix metalloproteinase (EMMPRIN/CD147), but elevates the expression of reversion-inducing cysteine-rich proteins with kazal motifs (RECK) and the tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2. In addition, sinomenine significantly increases the expression of the epithelial marker E-cadherin but concomitantly decreases the expression of the mesenchymal marker vimentin, suggesting that it suppresses epithelial–mesenchymal transition (EMT). Moreover, sinomenine downregulates oncogenic microRNA-21 (miR-21), which has been known to target RECK. The downregulation of miR-21 decreases cell invasion, while the upregulation of miR-21 increases cell invasion. Furthermore, the downregulation of miR-21 stimulates the expression of RECK, TIMP-1/-2, and E-cadherin, but reduces the expression of MMP-2/-9, EMMPRIN/CD147, and vimentin. Taken together, the results reveal that the inhibition of A549 cell invasion by sinomenine may, at least in part, be through the downregulating expression of MMPs and miR-21. These findings demonstrate an attractive therapeutic potential for sinomenine in lung cancer anti-metastatic therapy.

1. Introduction

Lung cancer is one of the most common types of malignant cancers in many countries. Non-small cell lung cancer accounts for approximately 85% of lung cancer with a generally poor prognosis and a high potential for metastasis [1]. For most patients with advanced and metastatic lung cancer, surgical resection may be not suitable, thus rendering cytotoxic treatments including chemotherapy and radiotherapy as major therapy strategies. Advanced lung cancer cells are highly invasive and result in high mortality rates. In order to improve the current therapeutic efficacy, developing more effective agents that target cancer cell invasion and metastasis is necessary.
Cancer metastasis is a complex process involving multiple steps, including the detachment of cells from the primary tumor, degradation of the extracellular matrix (ECM), invasion of cells to the surrounding tissue, entry into blood vessels or lymphatic vessels, and finally extravasation in new tissue [2,3]. Matrix metalloproteinases (MMPs) are important enzymes that contribute to tumor cell migration, invasion, and metastasis [4]. Of these MMPs, MMP-2 and MMP-9 are the major proteases that participate in the process of metastasis [5,6]. Activation of these enzymes is associated with increased tumor metastasis, which suggests a crucial function for these proteases in metastasis [7].
Degradation of the ECM is crucial for tumor invasion and metastasis. Several proteins are responsible for the ECM degradation and cell invasion, such as the extracellular inducer of matrix metalloproteinase (EMMPRIN/CD147), reversion-inducing, cysteine-rich proteins with kazal motifs (RECK) and tissue inhibitor of metalloproteinases (TIMPs). EMMPRIN/CD147 is highly expressed in various cancer cells and functions as an activator of proteinases including MMPs in tumor and neighboring stromal cells, and contributes to the regulation of the tumor microenvironment [8,9]. RECK is a membrane-anchored MMP inhibitor that negatively regulates activities of MMP-2 and MMP-9, and consequently reduces cancer invasion and metastasis [10]. A low expression of RECK is associated with a high invasiveness and poor prognosis [11]. TIMPs are endogenous tissue inhibitors that suppress activities of most MMPs. The balance between MMP and TIMP levels is a central determinant of the net proteolytic activity [12]. Tumor dissemination is also facilitated by the epithelial–mesenchymal transition (EMT) of tumor cells, through which cells exhibit greater motility and invasiveness [13,14]. The process of EMT is associated with the downregulation of epithelial markers such as E-cadherin, and the upregulation of mesenchymal markers such as vimentin [15].
MicroRNAs (miRNAs) represent a class of small non-coding RNAs that suppress the mRNA translation or stability by interacting with the target genes. miRNAs regulate multiple important biological processes including the cellular proliferation, differentiation, and pathogenesis of cancers [16,17]. Some miRNAs have been shown to serve as oncogenes or tumor suppressors [18,19]. An oncogenic miRNA, miR-21, is overexpressed in various tumors including lung, prostate, breast, pancreas, and colon [20,21]. miR-21 stimulates cancer cell proliferation, inhibits apoptosis, and increases invasion and metastasis by targeting multiple molecules such as programmed cell death (Pdcd4) [22], the phosphatase and tensin homolog gene (PTEN) [23], and RECK [24].
Sinomenine is an alkaloid extracted from Sinomenium acutum [25]. Previous studies have shown that sinomenine exhibits anti-inflammatory and anti-rheumatic effects [26,27]. In addition, sinomenine is effective in inhibiting proliferation and enhancing apoptosis of human cancer cell lines such as lung, gastric, liver, and breast cancers and glioblastoma [28,29,30,31,32]. Sinomenine also suppresses the migration and invasion of various human cancer cells [33,34,35,36]. Recent studies have demonstrated that sinomenine exerts anti-cancer activity by regulating various miRNAs. Sinomenine inhibits breast cancer cell migration and invasion by the modulation of miR-324-5p and miR-29 [33,35]. Sinomenine reveals anti-tumor activity by the induction of miR-204 in gastric cancer cells [37]. Moreover, sinomenine suppresses cell proliferation, migration and invasion by the downregulation of miR-23a [36].
Although sinomenine exerts anti-tumor potential against various cancer cell lines, the effect of sinomenine on miR-21-involved cancer cell migration and invasion remains unclear. This work determines the inhibitory effect and the molecular mechanisms of sinomenine on metastasis in vitro. A human lung adenocarcinoma cell is used in these experiments because of its highly invasive and metastatic characteristics. This study provides evidence that sinomenine can suppress the invasion of lung adenocarcinoma cells, suggesting a novel strategy for lung cancer treatment.

2. Results

2.1. Cytotoxic Effect of Sinomenine on A549 Cells

The chemical structure of sinomenine is shown in Figure 1A. The cytotoxic effect of sinomenine on human lung cancer A549 and H1299 cells is demonstrated in Figure 1B,C. The results reveal that treatment with 0.2 mM of sinomenine for 24 h significantly decreases the viability of A549 and H1299 cells, while treatment at doses below 0.1 mM does not cause cytotoxicity.

2.2. Effects of Sinomenine on Migration and Invasion of A549 Cells

In the view of cytotoxicity at a higher concentration of sinomenine, the inhibitory effect of non-toxic doses of sinomenine on the migration and invasion of A549 cells was investigated. After incubation with various concentrations of sinomenine for 24 h, 0.2 mM of sinomenine significantly suppresses the migration of A549 cells (Figure 2A,B). The inhibitory effect of sinomenine on the migration of H1299 cells was also observed (Figure 2C,D). These results demonstrate that sinomenine significantly inhibits the migration of A549 and H1299 cells.
In order to determine the inhibitory effect of sinomenine on the invasion of A549 cells across the extracellular matrix, the cells that invaded through the Matrigel-coated polycarbonate filter in the Boyden chamber were determined. The results show that sinomenine suppresses the invasion of A549 cells across the Matrigel-coated filter in a dose-dependent manner. Treatment with sinomenine at doses of 0.1 and 0.2 mM inhibited 26.5% and 40.8% of cell invasion, respectively (Figure 3A,B). The inhibitory effect of sinomenine on the invasion of H1299 cells across the Matrigel-coated filter was also observed (Figure 3C,D). These results indicate that sinomenine markedly inhibits the invasion of A549 and H1299 cells.

2.3. Sinomenine Decreases Expression of MMP-2, MMP-9, EMMPRIN/CD147 and Vimentin But Induces Expression of RECK, TIMP-1, TIMP-2 and E-Cadherin in A549 Cells

In order to investigate the mechanism of sinomenine on suppressing migration and invasion, A549 cells were used for the following experiments. During cell invasion, a proteolytic degradation of the ECM is required. Therefore, the effect of sinomenine on the expression of genes involved in the ECM degradation was analyzed by quantitative real-time PCR. The primer sequences are listed in Table 1. Data show that sinomenine decreases the mRNA expression of MMP-2, -9, and EMMPRIN/CD147 (Figure 4A). In addition, sinomenine enhances the expression of TIMP-1, -2, and RECK, which negatively regulate the activity of MMPs (Figure 4B). These results suggest that expressions of these genes involved in the degradation of the ECM are affected by sinomenine. Moreover, sinomenine significantly increases the expression of E-cadherin but decreases the expression of vimentin on the mRNA level in A549 cells (Figure 4C), suggesting sinomenine may induce the reversal of EMT.

2.4. Sinomenine Downregulates Expression of miR-21

Previous reports demonstrated that miR-21 is overexpressed in lung cancer cells in which miR-21 targets RECK and subsequently enhances cell invasion [20,24]. Quantitative real-time PCR was performed to detect the effect of sinomenine on the expression of miR-21. The result shows that sinomenine downregulates the expression of miR21 in a dose-dependent manner (Figure 5A). The decrease in the miR-21 expression by sinomenine may be involved in the anti-invasive mechanisms of sinomenine. To further investigate the role of miR-21 in the invasion of A549 cells, miR-21 mimics or inhibitors were transfected into A549 cells. The results demonstrate that cell invasion is elevated by the miR-21 mimics but reduced by the miR-21 inhibitors (Figure 5B). These findings indicate that the inhibition of the miR-21 expression may suppress cell invasion.

2.5. Silencing miR-21 Decreases Expression of MMP-2, MMP-9, EMMPRIN/CD147, and Vimentin but Induces Expression of RECK, TIMP-1, TIMP-2, and E-Cadherin in A549 Cells

To further investigate the effect of miR-21 on the expression of genes involved in cell invasion, quantitative real-time PCR was performed to detect the expression of genes after A549 cells were transfected with the miR-21 mimics or inhibitors. The results show that the miR-21 mimics decrease while the miR-21 inhibitors increase the expression of RECK, which is known as a target of miR-21. Moreover, the miR-21 inhibitors suppress the mRNA expression of MMP-2, -9, and EMMPRIN/CD147, but elevate the expression of TIMP-1/-2 (Figure 6A,B). The miR-21 inhibitors also increase the mRNA expression of E-cadherin but decrease the expression of vimentin (Figure 6C). These results reveal that the inhibition of the miR-21 expression may contribute to the expression of genes involved in the proteolytic activation and EMT, subsequently suppressing cell invasion.

3. Discussion

Sinomenine, the major bioactive alkaloid extracted from Sinomenium acutum, has been shown to possess anti-cancer activity against various cancer cell lines [29,30,31,32]. Our results demonstrate that sinomenine inhibits the viability of human lung cancer A549 and H1299 cells at the concentration of 0.2 mM. The results are consistent with a previous report that sinomenine induces cytotoxicity in A549 cells with an mM range [34]. Although the cytotoxic effect of sinomenine in the mM range has been reported in various cancer cell lines [30,33,34], the effect values in the μM range are reported. Sinomenine inhibits the viability of glioma U87 cells and clear-cell renal carcinoma ACHN cells in the μM range [38,39]. The sensitivity of the cytotoxic response of sinomenine is different in different cancer cell lines. The present findings demonstrate that sinomenine significantly suppresses the proliferation of human lung cancer A549 and H1299 cells. To elucidate the effect of sinomenine on cell motility, cell migration and invasion were determined by in vitro wound healing and Boyden chamber invasion assay, respectively. The present results reveal that sinomenine suppresses the migration and invasion of A549 and H1299 cells. In the Boyden chamber invasion assay, cells degrade the ECM components and perform transmigration across the ECM [40]. Pericellular proteolytic degradation of the ECM plays a critical role in tumor cell invasion, and is controlled by extracellular proteases, such as MMPs. Of these proteases, the expression of MMP-2 and MMP-9 are associated with lung cancer progression [41]. Previous reports also indicated that the downregulation of MMP-2 and MMP-9 inhibits the invasion and metastasis of lung cancer cells [41,42]. In view of this, whether the inhibitory effect of sinomenine on cell invasion is through the downregulating expression of MMPs was explored in A549 cells. The present results show that sinomenine suppresses the invasion and MMP-2/-9 expression in A549 cells, suggesting that sinomenine inhibits cell invasion through suppressing the MMP-2/-9 expression. The findings are consistent with previous reports showing that sinomenine inhibits invasion in various cancer cells through the downregulation of the MMP-2/-9 expression [36,43,44].
During tumor cell invasion, proteolytic degradation of the ECM is also regulated by various proteins. EMMPRIN/CD147 has been shown to activate MMPs, stimulate angiogenic factors in tumor and stromal cells, and modify the tumor microenvironment [8]. RECK negatively regulates the activity of MMPs and reduces cancer cell invasion, metastasis, and tumor angiogenesis [10]. The low expression of RECK in lung tumor tissues is associated with poor prognosis [45]. Recent reports implicated that the augmentation of the RECK expression can inhibit cancer cell invasion [46,47]. TIMPs act as the negative regulators of MMPs by which they are involved in the regulation of the invasion, metastasis, and angiogenesis of various cancers [48,49]. The upregulation of TIMP-1 contributes to inhibition of cancer cell invasion [50,51]. The results of this study suggest that the anti-invasive effect of sinomenine may attribute to the inhibition of the MMP-2/-9 and EMMPRIN/CD147 expressions, and the induction of the RECK and TIMP-1/-2 expressions.
The EMT of tumor cells plays an important role in cell migration and invasion. Stimulation of an EMT can cause cancer cells to invade the surrounding stroma, so a reversal of the EMT is thought to be an effective strategy against cancer metastasis [16]. This study observed the capability of sinomenine in reversing an EMT by downregulating the mesenchymal marker vimentin, and upregulating the epithelial marker E-cadherin. The results suggest that sinomenine induces the reversal of an EMT and may subsequently contribute to the inhibition of invasion in A549 cells.
Many miRNAs have been shown to regulate tumor initiation, invasion, metastasis, and angiogenesis [19]. Overexpression of oncomir miR-21 has been observed in many types of human cancers in which miR-21 promotes tumor initiation and invasion [20]. A recent study showed that miR-21 enhanced the invasion of lung cancer cells by targeting RECK, a negative regulator of several MMPs [24]. The present results demonstrate that sinomenine increases the RECK expression but decreases the miR-21 expression. In addition, the miR-21 mimics downregulate while the miR-21 inhibitors upregulate the expression of RECK. These findings imply that sinomenine stimulates the RECK expression through the downregulation of miR-21.
In order to elucidate whether the expression of MMP-2/-9, EMMPRIN/CD147, TIMP-1/-2, E-cadherin, and vimentin by sinomenine is regulated by the expression of miR-21, the miR-21 mimics and inhibitors were transfected to A549 cells and the gene expression was determined. The results demonstrate that the miR-21 inhibitors suppress the expression of MMP-2/-9, EMMPRIN/CD147, and vimentin, but elevate the expression of TIMP-1/-2 and E-cadherin. However, there is no evidence showing that miR-21 can directly target these genes. Therefore, miR-21 may regulate other pathways, which in turn affect the expression of the genes involved in cell invasion. Recent studies have demonstrated that miR-21 activates the PI3K/Akt signaling pathway by targeting PTEN, a negative regulator of the PI3K/Akt pathway [52,53]. Previous reports have indicated that the expression of the matrix metalloproteinases gene is mediated by the PI3K/Akt pathway [54,55]. In addition, miR-21 regulates the EMT in lung cancer cells through the PTEN/Akt signaling pathway [56]. Thus, miR-21 may affect the expression of MMP-2/-9, EMMPRIN/CD147, TIMP-1/-2, E-cadherin, and vimentin through mediating the PI3K/Akt/PTEN pathway.
NF-κB is crucial for the invasion and metastasis of some cancers [57,58]. Several naturally occurring anti-cancer agents inhibit migration and invasion in various cancer cell lines through the downregulation of NF-κB [59]. A previous report also demonstrated that sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB [33]. In addition, NF-κB is essential for an EMT, which is considered to be closely associated with invasion and metastasis [13]. In the present study, results show that sinomenine regulates the expression of MMP-2/-9, EMMPRIN/CD147, TIMP-1/-2, E-cadherin, and vimentin. Sinomenine may affect the expression of those genes by regulating the activity of NF-κB. For a further understanding the role of NF-κB on the anti-cancer effect of sinomenine, the effect of sinomenine on the activity of NF-κB will be investigated in the future. The inhibitors and specific siRNA of NF-κB (p65) will be used to elucidate the effect of sinomenine. Furthermore, an investigation of the anti-metastatic effect of sinomenine will be carried out in an animal model in the future. The therapeutic activity and pharmacodynamic characteristics of sinomenine in vivo will also be performed.

4. Materials and Methods

4.1. Reagents and Cell Culture

Sinomenine, dimethyl sulfoxide (DMSO), Tris-HCl, and EDTA were purchased from Sigma-Aldrich (St. Louis, MO, USA). A powdered Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Gibco/BRL (Gaithersburg, MD, USA). Matrigel was purchased from BD Bioscience (Franklin, NJ, USA). The total RNA extraction kit and PCR kit were from Invitrogen (Carlsbad, CA, USA). The FastStart Universal Probe Master assay kit was purchased from Roche Applied Science. The human lung adenocarcinoma cell line A549 was obtained from BCRC (Food Industry Research and Development Institute, Hsinchu, Taiwan). The human non-small cell lung carcinoma cell line H1299 was a gift from Dr. Ying-Jan Wang (Department of Environmental and Occupational Health, National Cheng Kung University, Tainan, Taiwan). Cells were maintained in the DMEM supplemented with 10% fetal calf serum, 100 U/mL of penicillin, and 100 µg/mL streptomycin, and incubated in a 5% CO2-humidified incubator at 37 °C. For the sinomenine treatment, sinomenine was dissolved in DMSO and diluted with a culture medium (the final concentration of ethanol was less than 0.2%).

4.2. Cell Viability Assay

The assay was performed as described previously [60]. Briefly, 3 × 103 cells were seeded in a 96-well plate and treated with sinomenine in triplicate. After 24 h of incubation, the medium was replaced with a fresh medium containing 0.5 mg/mL MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. After 4 h, the supernatants were removed and the resulting MTT formazan was solubilized in DMSO and measured spectrophotometrically at 570 nm.

4.3. Wound Healing Migration Assay

The assay was performed as described previously [61]. A549 cells were plated in a 12-well plate and grew to confluence. The monolayer culture was then scrape-wounded with a sterile micropipette tip to create a denuded zone (gap) of a constant width. After removing the cellular debris with PBS, cells were exposed to various concentrations of sinomenine for 24 h. A549 cells that migrated to the wounded region were observed by an Olympus CK-2 inverted microscope and photographed (100× magnification). The wound area was measured by the program Image J (http://rsb.info.nih.gov/ij/). The percentage of wound closure was estimated by the following equation: Wound closure % = [1 − (wound area at Tt/wound area at T0) × 100%], where Tt is the time after wounding and T0 is the time immediately after wounding.

4.4. Boyden Chamber Invasion Assay

The Boyden chamber invasion assay was carried out as previously described [56]. Briefly, the polycarbonate filter (8 µm pore) was pre-coated with Matrigel. After being treated with sinomenine for 24 h, the cells (6 × 103 cells/well) were added to the upper chamber in a serum-free medium. The complete medium (containing 10% FBS) was applied to the lower chamber as a chemoattractant. The chamber was incubated for 6 h at 37 °C. At the end of incubation, the cells in the upper surface of the membrane were carefully removed with a cotton swab and the cells that invaded the lower surface of the membrane were fixed with methanol and stained with a 5% Giemsa solution. The invaded cells on the lower surface of the membrane filter were scored from five random fields under microscopy (200× magnification).

4.5. Gene Expression Analysis

The total RNA was extracted using a TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The total RNA (1 µg) from each sample was subject to reverse transcription with oligo (dT) primers by a PCR kit according to manufacturer’s instruction. The mRNA expressions of MMP-2, -9, EMMPRIN/CD147, TIMP-1,-2, and RECK were determined by quantitative real-time PCR which was conducted in the StepOne system (Applied Biosystem, Foster City, CA, USA). Briefly, each amplification mixture (50 μL) contained 10 ng cDNA and 25 μL SYBR Green PCR Master Mix. The PCR conditions were as follows: 95 °C for 2 min, 40 cycles at 95 °C for 15 s, and 60 °C for 45 s. For the detection of miR-21, a FastStart Universal Probe Master assay kit (Roche Applied Science, Penzberg, Germany) was used according to manufacturer’s instruction, and RNU6B was used as the internal control. The primer sequences are listed in Table 1. The PCR results were derived using the comparative CT method. The chemically synthesized miR-21 mimics, miR-21 inhibitors, and the corresponding scramble negative controls were purchased from Quantum Biotechnology (Taichung, Taiwan). A549 cells were transfected with 50 nM miR-21 mimics, or 30 nM miR-21 inhibitors by the Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).

4.6. Statistical Analysis

The data were expressed as mean ± standard deviation. The statistical significance was analyzed by a one-way ANOVA. If the significance was observed, the Dunnett’s post-hoc test was used to determine the difference between the treatment groups and the untreated group, with values of p < 0.05 considered statistically significant.

5. Conclusions

In conclusion, the present results reveal the anti-invasive effect of sinomenine in human lung cancer cells. The regulation in the expression of MMP-2/9, EMMPRIN/CD147, TIMP-1/-2, RECK, E-cadherin, and vimentin by sinomenine is possibly caused by the expression of miR-21. The effect of sinomenine on regulating the expression of these genes and miR-21 may result in the inhibition of invasion in lung cancer cells. The present study is the first report that indicates sinomenine downregulates the expression of miR-21, by which sinomenine suppresses migration and invasion in human lung carcinoma cells. The current findings disclose a new therapeutic potential of sinomenine in lung cancer therapy.

Author Contributions

Conceptualization, K.-H.S., J.-H.H. and P.-S.C.; Methodology, J.-H.H., Y.-C.L., S.-T.T. and M.-J.W.; Software, Y.-C.L. and S.-T.T.; Validation, Y.-C.L. and S.-T.T.; Formal Analysis, P.-S.C.; Investigation, K.-H.S., J.-H.H. and P.-S.C.; Resources, J.-H.H., M.-J.W. and P.-S.C.; Data Curation, P.-S.C.; Writing—Original Draft Preparation, P.-S.C.; Writing—Review & Editing, P.-S.C.; Visualization, P.-S.C.; Supervision, P.-S.C.; Project Administration, P.-S.C.; Funding Acquisition, K.-H.S. and P.-S.C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the grant from Chi Mei Medical Center, Tainan, Taiwan (Grant number: CMFHR10662).

Acknowledgments

We thank Chia-Wei Chang and Pei-Yu Chao for experimental assistances.

Conflicts of Interest

The authors declare that there are no conflict of interest.

References

  1. Shivapurkar, N.; Reddy, J.; Chaudhary, P.M.; Gazdar, A.F. Apoptosis and lung cancer: A review. J. Cell. Biochem. 2003, 88, 885–898. [Google Scholar] [CrossRef] [PubMed]
  2. Gupta, G.P.; Massague, J. Cancer metastasis: Building a framework. Cell 2006, 127, 679–695. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Meyer, T.; Hart, I.R. Mechanisms of tumour metastasis. Eur. J. Cancer 1998, 34, 214–221. [Google Scholar] [CrossRef]
  4. Itoh, Y.; Nagase, H. Matrix metalloproteinases in cancer. Essays Biochem. 2002, 38, 21–36. [Google Scholar] [PubMed] [Green Version]
  5. Bernhard, E.J.; Gruber, S.B.; Muschel, R.J. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA 1994, 91, 4293–4297. [Google Scholar] [CrossRef] [Green Version]
  6. Emmert-Buck, M.R.; Roth, M.J.; Zhuang, Z.; Campo, E.; Rozhin, J.; Sloane, B.F.; Liotta, L.A.; Stetler-Stevenson, W.G. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am. J. Pathol. 1994, 145, 1285–1290. [Google Scholar]
  7. Mook, O.R.; Frederiks, W.M.; Van Noorden, C.J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim. Biophys. Acta 2004, 1705, 69–89. [Google Scholar] [CrossRef]
  8. Nabeshima, K.; Iwasaki, H.; Koga, K.; Hojo, H.; Suzumiya, J.; Kikuchi, M. Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol. Int. 2006, 56, 359–367. [Google Scholar] [CrossRef]
  9. Xu, X.Y.; Lin, N.; Li, Y.M.; Zhi, C.; Shen, H. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer. Pathol. Res. Pract. 2013, 209, 345–352. [Google Scholar] [CrossRef]
  10. Clark, J.C.; Thomas, D.M.; Choong, P.F.; Dass, C.R. RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev. 2007, 26, 675–683. [Google Scholar] [CrossRef]
  11. Takenaka, K.; Ishikawa, S.; Kawano, Y.; Yanagihara, K.; Miyahara, R.; Otake, Y.; Morioka, Y.; Takahashi, C.; Noda, M.; Wada, H.; et al. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur. J. Cancer 2004, 40, 1617–1623. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Sun, J. Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells. J. Signal. Transuct. 2010, 2010, 985132–985139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Tsai, J.H.; Yang, J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes. Dev. 2013, 27, 2192–2206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Wells, A.; Chao, Y.L.; Grahovac, J.; Wu, Q.; Lauffenburger, D.A. Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front. Biosci. 2011, 16, 815–837. [Google Scholar] [CrossRef] [Green Version]
  15. Zeisberg, M.; Neilson, E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119, 1429–1437. [Google Scholar] [CrossRef] [Green Version]
  16. Zhao, Y.; Srivastava, D. A developmental view of microRNA function. Trends Biochem. Sci. 2007, 32, 189–197. [Google Scholar] [CrossRef]
  17. Kumar, M.S.; Lu, J.; Mercer, K.L.; Golub, T.R.; Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39, 673–677. [Google Scholar] [CrossRef]
  18. Esquela-Kerscher, A.; Slack, F.J. Oncomirs—MicroRNAs with a role in cancer. Nat. Rev. 2006, 6, 259–269. [Google Scholar] [CrossRef]
  19. Manikandan, J.; Aarthi, J.J.; Kumar, S.D.; Pushparaj, P.N. Oncomirs: The potential role of non-coding microRNAs in understanding cancer. Bioinformation 2008, 2, 330–334. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Markou, A.; Tsaroucha, E.G.; Kaklamanis, L.; Fotinou, M.; Georgoulias, V.; Lianidou, E.S. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem. 2008, 54, 1696–1704. [Google Scholar] [CrossRef]
  21. Krichevsky, A.M.; Gabriely, G. miR-21: A small multi-faceted RNA. J. Cell. Mol. Med. 2009, 13, 39–53. [Google Scholar] [CrossRef] [PubMed]
  22. Asangani, I.A.; Rasheed, S.A.; Nikolova, D.A.; Leupold, J.H.; Colburn, N.H.; Post, S.; Allgayer, H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27, 2128–2136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133, 647–658. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Xu, L.F.; Wu, Z.P.; Chen, Y.; Zhu, Q.S.; Hamidi, S.; Navab, R. MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China. PLoS ONE 2014, 9, e103698. [Google Scholar] [CrossRef] [Green Version]
  25. Zhao, X.X.; Peng, C.; Zhang, H.; Qin, L.P. Sinomenium acutum: A review of chemistry, pharmacology, pharmacokinetics, and clinical use. Pharm. Biol. 2012, 50, 1053–1061. [Google Scholar] [CrossRef]
  26. Teng, P.; Liu, H.L.; Zhang, L.; Feng, L.L.; Huai, Y.; Deng, Z.S.; Sun, Y.; Xu, Q.; Li, J.X. Synthesis and biological evaluation of novel sinomenine derivatives as anti-inflammatory agents. Eur. J. Med. Chem. 2012, 50, 63–74. [Google Scholar] [CrossRef]
  27. Wang, Y.; Fang, Y.; Huang, W.; Zhou, X.; Wang, M.; Zhong, B.; Peng, D. Effect of sinomenine on cytokine expression of macrophages and synoviocytes in adjuvant arthritis rats. J. Ethnopharmacol. 2005, 98, 37–43. [Google Scholar] [CrossRef]
  28. Jiang, Y.; Jiao, Y.; Wang, Z.; Li, T.; Liu, Y.; Li, Y.; Zhao, X.; Wang, D. Sinomenine Hydrochloride Inhibits Human Glioblastoma Cell Growth through Reactive Oxygen Species Generation and Autophagy-Lysosome Pathway Activation: An In Vitro and In Vivo Study. Int. J. Mol. Sci. 2017, 18, 1945. [Google Scholar] [CrossRef] [Green Version]
  29. Jiang, T.; Zhou, L.; Zhang, W.; Qu, D.; Xu, X.; Yang, Y.; Li, S. Effects of sinomenine on proliferation and apoptosis in human lung cancer cell line NCI-H460 in vitro. Mol. Med. Rep. 2010, 3, 51–56. [Google Scholar]
  30. Lv, Y.; Li, C.; Li, S.; Hao, Z. Sinomenine inhibits proliferation of SGC-7901 gastric adenocarcinoma cells via suppression of cyclooxygenase-2 expression. Oncol. Lett. 2011, 2, 741–745. [Google Scholar] [CrossRef] [Green Version]
  31. Lu, X.L.; Zeng, J.; Chen, Y.L.; He, P.M.; Wen, M.X.; Ren, M.D.; Hu, Y.N.; Lu, G.F.; He, S. Sinomenine hydrochloride inhibits human hepatocellular carcinoma cell growth in vitro and in vivo: Involvement of cell cycle arrest and apoptosis induction. Int. J. Oncol. 2013, 42, 229–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Li, X.; Wang, K.; Ren, Y.; Zhang, L.; Tang, X.J.; Zhang, H.M.; Zhao, C.Q.; Liu, P.J.; Zhang, J.M.; He, J.J. MAPK signaling mediates sinomenine hydrochloride-induced human breast cancer cell death via both reactive oxygen species-dependent and -independent pathways: An in vitro and in vivo study. Cell Death Dis. 2014, 5, e1356. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Song, L.; Liu, D.; Zhao, Y.; He, J.; Kang, H.; Dai, Z.; Wang, X.; Zhang, S.; Zan, Y. Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis. Biochem. Biophys. Res. Commun. 2015, 464, 705–710. [Google Scholar] [CrossRef] [PubMed]
  34. Jiang, S.; Gao, Y.; Hou, W.; Liu, R.; Qi, X.; Xu, X.; Li, J.; Bao, Y.; Zheng, H.; Hua, B. Sinomenine inhibits A549 human lung cancer cell invasion by mediating the STAT3 signaling pathway. Oncol. Lett. 2016, 12, 1380–1386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Gao, G.; Liang, X.; Ma, W. Sinomenine restrains breast cancer cells proliferation, migration and invasion via modulation of miR-29/PDCD-4 axis. Artif. Cells Nanomed. Biotechnol. 2019, 47, 3839–3846. [Google Scholar] [CrossRef] [Green Version]
  36. Xu, F.; Li, Q.; Wang, Z.; Cao, X. Sinomenine inhibits proliferation, migration, invasion and promotes apoptosis of prostate cancer cells by regulation of miR-23a. Biomed. Pharmacother. Biomed. Pharmacother. 2019, 112, 108592. [Google Scholar] [CrossRef]
  37. Yuan, H.; Zhang, J.; Li, F.; Li, W.; Wang, H. Sinomenine exerts antitumour effect in gastric cancer cells via enhancement of miR-204 expression. Basic Clin. Pharmacol. Toxicol. 2019, 125, 450–459. [Google Scholar] [CrossRef]
  38. Zhao, B.; Liu, L.; Mao, J.; Liu, K.; Fan, W.; Liu, J.; Zhang, Z.; Li, Q. Sinomenine hydrochloride attenuates the proliferation, migration, invasiveness, angiogenesis and epithelial-mesenchymal transition of clear-cell renal cell carcinoma cells via targeting Smad in vitro. Biomed. Pharmacother. 2017, 96, 1036–1044. [Google Scholar] [CrossRef]
  39. He, X.; Maimaiti, M.; Jiao, Y.; Meng, X.; Li, H. Sinomenine Induces G1-Phase Cell Cycle Arrest and Apoptosis in Malignant Glioma Cells Via Downregulation of Sirtuin 1 and Induction of p53 Acetylation. Technol. Cancer Res. Treat. 2018, 17, 1533034618770305. [Google Scholar] [CrossRef] [Green Version]
  40. Friedl, P.; Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. 2003, 3, 362–374. [Google Scholar] [CrossRef]
  41. Bodey, B.; Bodey, B., Jr.; Groger, A.M.; Siegel, S.E.; Kaiser, H.E. Invasion and metastasis: The expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo 2001, 15, 175–180. [Google Scholar]
  42. Hrabec, E.; Strek, M.; Nowak, D.; Greger, J.; Suwalski, M.; Hrabec, Z. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: A quantitative analysis. J. Cancer Res. Clin. Oncol. 2002, 128, 197–204. [Google Scholar] [CrossRef]
  43. Xie, T.; Ren, H.Y.; Lin, H.Q.; Mao, J.P.; Zhu, T.; Wang, S.D.; Ye, Z.M. Sinomenine prevents metastasis of human osteosarcoma cells via S phase arrest and suppression of tumor-related neovascularization and osteolysis through the CXCR4-STAT3 pathway. Int. J. Oncol. 2016, 48, 2098–2112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Jiang, Y.; Jiao, Y.; Liu, Y.; Zhang, M.; Wang, Z.; Li, Y.; Li, T.; Zhao, X.; Wang, D. Sinomenine Hydrochloride Inhibits the Metastasis of Human Glioblastoma Cells by Suppressing the Expression of Matrix Metalloproteinase-2/-9 and Reversing the Endogenous and Exogenous Epithelial-Mesenchymal Transition. Int. J. Mol. Sci. 2018, 19, 844. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Takemoto, N.; Tada, M.; Hida, Y.; Asano, T.; Cheng, S.; Kuramae, T.; Hamada, J.; Miyamoto, M.; Kondo, S.; Moriuchi, T. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Lung Cancer 2007, 58, 376–383. [Google Scholar] [CrossRef] [PubMed]
  46. Kato, K.; Long, N.K.; Makita, H.; Toida, M.; Yamashita, T.; Hatakeyama, D.; Hara, A.; Mori, H.; Shibata, T. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br. J. Cancer 2008, 99, 647–654. [Google Scholar] [CrossRef] [Green Version]
  47. Rabien, A.; Ergun, B.; Erbersdobler, A.; Jung, K.; Stephan, C. RECK overexpression decreases invasive potential in prostate cancer cells. Prostate 2012, 72, 948–954. [Google Scholar] [CrossRef]
  48. Gomez, D.E.; Alonso, D.F.; Yoshiji, H.; Thorgeirsson, U.P. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur. J. Cell Biol. 1997, 74, 111–122. [Google Scholar]
  49. Pulukuri, S.M.; Patibandla, S.; Patel, J.; Estes, N.; Rao, J.S. Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 2007, 26, 5229–5237. [Google Scholar] [CrossRef] [Green Version]
  50. Ramer, R.; Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl. Cancer Inst. 2008, 100, 59–69. [Google Scholar] [CrossRef] [Green Version]
  51. Ramer, R.; Merkord, J.; Rohde, H.; Hinz, B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem. Pharmacol. 2010, 79, 955–966. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Wu, Y.R.; Qi, H.J.; Deng, D.F.; Luo, Y.Y.; Yang, S.L. MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer. Tumour Biol. 2016, 37, 12061–12070. [Google Scholar] [CrossRef] [PubMed]
  53. Liu, Z.L.; Wang, H.; Liu, J.; Wang, Z.X. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol. Cell. Biochem. 2013, 372, 35–45. [Google Scholar] [CrossRef] [PubMed]
  54. Kim, D.; Kim, S.; Koh, H.; Yoon, S.O.; Chung, A.S.; Cho, K.S.; Chung, J. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 2001, 15, 1953–1962. [Google Scholar]
  55. Chakraborti, S.; Mandal, M.; Das, S.; Mandal, A.; Chakraborti, T. Regulation of matrix metalloproteinases: An overview. Mol. Cell. Biochem. 2003, 253, 269–285. [Google Scholar] [CrossRef] [PubMed]
  56. Dai, L.; Chen, F.; Zheng, Y.; Zhang, D.; Qian, B.; Ji, H.; Long, F.; Cretoiu, D. miR-21 regulates growth and EMT in lung cancer cells via PTEN/Akt/GSK3beta signaling. Front. Biosci. 2019, 24, 1426–1439. [Google Scholar]
  57. Sethi, G.; Ahn, K.S.; Sung, B.; Aggarwal, B.B. Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol. Cancer Ther. 2008, 7, 1604–1614. [Google Scholar] [CrossRef] [Green Version]
  58. Shin, E.M.; Hay, H.S.; Lee, M.H.; Goh, J.N.; Tan, T.Z.; Sen, Y.P.; Lim, S.W.; Yousef, E.M.; Ong, H.T.; Thike, A.A.; et al. DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J. Clin. Investig. 2014, 124, 3807–3824. [Google Scholar] [CrossRef]
  59. Safe, S.; Kasiappan, R. Natural Products as Mechanism-based Anticancer Agents: Sp Transcription Factors as Targets. Phytother. Res. 2016, 30, 1723–1732. [Google Scholar] [CrossRef]
  60. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63. [Google Scholar] [CrossRef]
  61. Lu, M.K.; Shih, Y.W.; Chang Chien, T.T.; Fang, L.H.; Huang, H.C.; Chen, P.S. alpha-Solanine inhibits human melanoma cell migration and invasion by reducing matrix metalloproteinase-2/9 activities. Biol. Pharm. Bull. 2010, 33, 1685–1691. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Ijms 21 03080 g001 550
Figure 1. Sinomenine inhibits viability of human lung cancer cells. (A) Chemical structure of sinomenine. (B) Effect of sinomenine on viability of A549 and H1299 cells. Cells were treated with various concentrations of sinomenine for 24 h. Cell viability is presented as mean ± S.D. of four independent experiments. ** p < 0.01 compared with the untreated control.
Figure 1. Sinomenine inhibits viability of human lung cancer cells. (A) Chemical structure of sinomenine. (B) Effect of sinomenine on viability of A549 and H1299 cells. Cells were treated with various concentrations of sinomenine for 24 h. Cell viability is presented as mean ± S.D. of four independent experiments. ** p < 0.01 compared with the untreated control.
Ijms 21 03080 g001
Ijms 21 03080 g002 550
Figure 2. Effect of sinomenine on migration of A549 and H1299 cells. (A) A549 cell monolayers were scraped by a sterile micropipette tip and the cells were treated with various doses of sinomenine for 24 h. Cells that migrated to the wounded region were photographed (100× magnification). The wound area of the cultures of A549 cells (B) and H1299 cells (C) were quantified in four fields in each treatment, and data were calculated from three independent experiments. Data are presented as mean ± S.D. of three independent experiments. * p < 0.05 compared with the untreated control.
Figure 2. Effect of sinomenine on migration of A549 and H1299 cells. (A) A549 cell monolayers were scraped by a sterile micropipette tip and the cells were treated with various doses of sinomenine for 24 h. Cells that migrated to the wounded region were photographed (100× magnification). The wound area of the cultures of A549 cells (B) and H1299 cells (C) were quantified in four fields in each treatment, and data were calculated from three independent experiments. Data are presented as mean ± S.D. of three independent experiments. * p < 0.05 compared with the untreated control.
Ijms 21 03080 g002
Ijms 21 03080 g003 550
Figure 3. Effect of sinomenine on the invasion of A549 and H1299 cells. (A) A549 cells were treated with various concentrations of sinomenine for 24 h and cell invasion assay was performed. The invaded cells were photographed (200× magnification). The invaded A549 cells (B) and H1299 cells (C) were counted in five random fields in each treatment, and data were calculated from three independent experiments. Data are presented as mean ± S.D. of three independent experiments. ** p < 0.01, *** p < 0.001 compared with the untreated control.
Figure 3. Effect of sinomenine on the invasion of A549 and H1299 cells. (A) A549 cells were treated with various concentrations of sinomenine for 24 h and cell invasion assay was performed. The invaded cells were photographed (200× magnification). The invaded A549 cells (B) and H1299 cells (C) were counted in five random fields in each treatment, and data were calculated from three independent experiments. Data are presented as mean ± S.D. of three independent experiments. ** p < 0.01, *** p < 0.001 compared with the untreated control.
Ijms 21 03080 g003
Ijms 21 03080 g004 550
Figure 4. Effect of sinomenine on the expressions of MMP-2/-9, EMMPRIN/CD147, TIMP-1/-2, RECK, E-cadherin, and vimentin in A549 cells. Cells were treated with various concentrations of sinomenine for 24 h and the expressions of MMP-2, MMP-9, and EMMPRIN/CD147 mRNA (A), TIMP-1, TIMP-2, and RECK (B), and E-cadherin and vimentin (C) were analyzed by quantitative real-time PCR. Data are expressed as mean ± S.D. of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the untreated control.
Figure 4. Effect of sinomenine on the expressions of MMP-2/-9, EMMPRIN/CD147, TIMP-1/-2, RECK, E-cadherin, and vimentin in A549 cells. Cells were treated with various concentrations of sinomenine for 24 h and the expressions of MMP-2, MMP-9, and EMMPRIN/CD147 mRNA (A), TIMP-1, TIMP-2, and RECK (B), and E-cadherin and vimentin (C) were analyzed by quantitative real-time PCR. Data are expressed as mean ± S.D. of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the untreated control.
Ijms 21 03080 g004
Ijms 21 03080 g005 550
Figure 5. Effects of sinomenine on the expression of miR-21. (A) Cells were treated with various concentrations of sinomenine for 24 h and the expressions of miR-21 were analyzed by quantitative real-time PCR. (B) A549 cells were transfected with the miR-21 negative control (miR-21 NC), miR-21 mimics, or mir-21 inhibitors for 48 hrs. Cell invasion was performed by Boyden chamber invasion assay. Data are expressed as mean ± S.D. of three independent experiments. ** p < 0.01, *** p < 0.001 compared with the untreated control.
Figure 5. Effects of sinomenine on the expression of miR-21. (A) Cells were treated with various concentrations of sinomenine for 24 h and the expressions of miR-21 were analyzed by quantitative real-time PCR. (B) A549 cells were transfected with the miR-21 negative control (miR-21 NC), miR-21 mimics, or mir-21 inhibitors for 48 hrs. Cell invasion was performed by Boyden chamber invasion assay. Data are expressed as mean ± S.D. of three independent experiments. ** p < 0.01, *** p < 0.001 compared with the untreated control.
Ijms 21 03080 g005
Ijms 21 03080 g006 550
Figure 6. Effect of miR-21 on the expressions of MMP-2/-9, EMMPRIN/CD147, TIMP-1/-2, RECK, E-cadherin, and vimentin in A549 cells. A549 cells were transfected with the miR-21 negative control, miR-21 mimics, or mir-21 inhibitors for 48 hrs. Cells were harvested and the expressions of MMP-2, MMP-9, and EMMPRIN/CD147 mRNA (A), TIMP-1, TIMP-2, and RECK (B), and E-cadherin and vimentin (C) were analyzed by quantitative real-time PCR. Data are expressed as mean ± S.D. of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the untreated control.
Figure 6. Effect of miR-21 on the expressions of MMP-2/-9, EMMPRIN/CD147, TIMP-1/-2, RECK, E-cadherin, and vimentin in A549 cells. A549 cells were transfected with the miR-21 negative control, miR-21 mimics, or mir-21 inhibitors for 48 hrs. Cells were harvested and the expressions of MMP-2, MMP-9, and EMMPRIN/CD147 mRNA (A), TIMP-1, TIMP-2, and RECK (B), and E-cadherin and vimentin (C) were analyzed by quantitative real-time PCR. Data are expressed as mean ± S.D. of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the untreated control.
Ijms 21 03080 g006
Table
Table 1. Primer pairs used in quantitative real-time PCR.
Table 1. Primer pairs used in quantitative real-time PCR.
GeneSequence (5′-3′)
MMP-2-FCTTCCAAGTCTGGAGCGATGT
MMP-2-RTACCGTCAAAGGGGTATCCAT
MMP-9-FGGGACGCAGACATCGTCATC
MMP-9-RTCGTCATCGTCGAAATGGGC
EMMPRIN-FCTACACATTGAGAACCTGAACAT
EMMPRIN-RTTCTCGTAGATGAAGATGATGGT
RECK-FCCTGCATTGCTCGCTGTGTG
RECK-RCCTGTGGTTTGGGTATGCACCTT
TIMP-1-FCTTCTGCAATTCCGACCTCGT
TIMP-1-RCCCTAAGGCTTGGAACCCTTT
TIMP-2-FAAGCGGTCAGTGAGAAGGAAG
TIMP-2-RCACACACTACCGAGGAGGG
β-actin-FCATGTACGTTGCTATCCAGGC
β-actin-RCTCCTTAATGTCACGCACGAT
E-cadherin-FACCAGAATAAAGACCAAGTGACCA
E-cadherin-RAGCAAGAGCAGCAGAATCAGAAT
vimentin-FAATGGCTCGTCACCTTCGTGAAT
vimentin-RCAGATTATG TTCCCTCAGGTTCAG
miR-21CGGCGGTAGCTTATCAGACTGA
RNU6BTTCCTCCGCAAGGATGACACGC

Share and Cite

MDPI and ACS Style

Shen, K.-H.; Hung, J.-H.; Liao, Y.-C.; Tsai, S.-T.; Wu, M.-J.; Chen, P.-S. Sinomenine Inhibits Migration and Invasion of Human Lung Cancer Cell through Downregulating Expression of miR-21 and MMPs. Int. J. Mol. Sci. 2020, 21, 3080. https://doi.org/10.3390/ijms21093080

AMA Style

Shen K-H, Hung J-H, Liao Y-C, Tsai S-T, Wu M-J, Chen P-S. Sinomenine Inhibits Migration and Invasion of Human Lung Cancer Cell through Downregulating Expression of miR-21 and MMPs. International Journal of Molecular Sciences. 2020; 21(9):3080. https://doi.org/10.3390/ijms21093080

Chicago/Turabian Style

Shen, Kun-Hung, Jui-Hsiang Hung, Yi-Ching Liao, Shu-Ting Tsai, Ming-Jiuan Wu, and Pin-Shern Chen. 2020. "Sinomenine Inhibits Migration and Invasion of Human Lung Cancer Cell through Downregulating Expression of miR-21 and MMPs" International Journal of Molecular Sciences 21, no. 9: 3080. https://doi.org/10.3390/ijms21093080

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop